Search results
Results from the WOW.Com Content Network
Alnylam to Webcast R&D Day CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, today announced that it will webcast its upcoming R ...
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023. [40] In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension ...
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a biotech company developing a new class of medications based on RNAi technology, have soared 250% since the start of 2013. Why are investors so ...
Robert J. Desnick is an American human geneticist whose basic and translational research accomplishments include significant discoveries in genomics, pharmacogenetics, gene therapy, personalized medicine, and the treatment of genetic diseases.
There, she was vice-president and medical director on the executive team of GSK's UK subsidiary. She then became GSK's Senior Vice President and Chief of Strategy and R&D. She was named in the 2011 Powerlist of Britain's Most Influential Black People. [2] In the 2012 Powerlist she was named at number five. [3]
(Reuters) -Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID ...
For premium support please call: 800-290-4726 more ways to reach us
The R&D and marketing spends address consumer needs while providing value for shareholders, as was seen with Botox. [28] The rejection by Allergan, however, did not prevent Valeant and Pershing from pursuing the Botox maker further. [29] Originally offering $48.30 per share, Valeant increased the cash portion of its offer to $58.30 per share. [30]